Silence (NASDAQ:SLN) earns $2M milestone in genetic research

Silence Therapeutics (NASDAQ:SLN) announced its achievement of a $2 million milestone payment from Hansoh Pharmaceutical Group.

This payment is part of their ongoing collaboration, following the attainment of a crucial, yet undisclosed, research milestone related to their joint project targeting genetic diseases.

The partnership, formalized in October 2021, focuses on developing siRNAs using Silence’s mRNAi GOLD™ platform for three undisclosed targets.